Re­silience al­lo­cates $225M to ex­pand man­u­fac­tur­ing ca­pac­i­ty in Cincin­nati

Na­tion­al Re­silience is work­ing to ex­pand its clin­i­cal and com­mer­cial drug man­u­fac­tur­ing ca­pa­bil­i­ties to pro­vide more than 200 mil­lion units to its clients by 2025.

Re­silience plans to in­vest at least $225 mil­lion in­to its Cincin­nati site, which is ded­i­cat­ed to fill­ing vials, car­tridges and pre-filled sy­ringes, a com­pa­ny re­lease states. The num­ber of high-speed fill lines should in­crease from three to four by 2025, while the num­ber of de­vice as­sem­bly and pack­ag­ing suites should grow to six.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.